<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292784</url>
  </required_header>
  <id_info>
    <org_study_id>200722</org_study_id>
    <nct_id>NCT02292784</nct_id>
  </id_info>
  <brief_title>Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies</brief_title>
  <acronym>ARIOS</acronym>
  <official_title>Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and outcomes of infants and
      children who were exposed to retosiban or comparator in utero in the planned Phase III
      spontaneous preterm labor (SPTL) treatment studies, to provide assurance that treatment is
      not associated with significant adverse outcomes in early childhood. The enrolled infants and
      children will be followed at pre-specified intervals until they reach 5 years chronological
      age. This study does not require medical interventions or study visits to an investigational
      site, instead, parents or legal guardians will be prompted at certain time points to complete
      developmental questionnaires and other data on their children's health status via an
      electronic device. Data collected during the infant and child follow up study will be managed
      by a centralized research coordinating center (RCC). Regionally based pediatricians will
      serve as study principal investigators (referred to as RCC-PIs) for this study. All
      communications the RCC-PI has with the parent/legal guardian or the child's health care
      provider (HCP) will occur remotely; there will be no clinic visits.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of infants and children with newly diagnosed (after 28 days post estimated date of delivery) chronic medical conditions</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Chronic medical conditions will include: respiratory (chronic lung disease, reactive airway disease, vocal cord paralysis, airway obstruction), neurological (cerebral palsy, seizure disorder, hydrocephalus requiring shunt), sensory (vision [vision impairment, blindness in 1 or both eyes], hearing [hearing impairment, deafness in 1 or both ears, hearing impaired defined as uncorrected even with aids]), gastrointestinal (gastroesophageal reflux disease, tube/parenteral feeding, short bowel syndrome), cardiovascular (pulmonary hypertension, hypertension), renal (renal impairment requiring dialysis), growth parameters (poor weight gain, reduced length, reduced head circumference, failure to thrive)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infants and children with newly diagnosed congenital anomalies</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A congenital anomaly is a condition present at birth that results from malformation, deformation, or disruption in 1 or more parts of the body, a chromosomal abnormality, or a known clinical syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infant and child deaths</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of infant and child deaths that occur after 28 days post estimated date of delivery (EDD) and until the end of the study (up to 5 years chronological age) will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with an Ages and Stages Questionnaire-3[ASQ-3] score in the black zone for any domain, for gross motor skills, for fine motor skills, for communication, for problem solving and for personal-social skills</measure>
    <time_frame>At 9, 18 and 24 months, corrected for prematurity, up to 24 months</time_frame>
    <description>The parent/legal guardian will be asked to complete standardized developmental screening of the infant through completion of the ASQ-3. The ASQ-3 includes a series of questions designed to assess 5 areas of development: communication, gross motor, fine motor, problem solving, and personal social. The questions target behaviours that are appropriate for particular developmental milestones.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants referred for developmental evaluation (using Bayley Scales of Infant Development, third edition (BSID III)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>If any of the child's ASQ-3 scores are in the black zone (&gt;/=2 SD below the mean), the child's parent/legal guardian will be asked if the child is already under the care of a developmental specialist who can or has made a formal assessment (e.g., using the BSID-III). If the child is not currently under the care of a developmental specialist, then the parent/legal guardian will be referred to a qualified assessor for developmental evaluation using the BSID-III.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with a BSID-III score &gt;2 SD below the mean score for the cognitive scale (&lt;70), for the gross motor scale (&lt;70), for the fine motor scale (&lt;70) and for the language scale (&lt;70)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>BSID-III is a tool used for developmental evaluation of the child.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with a Child Behavior Checklist (CBCL/1.5-5) score at or above the 97th percentile for a subset of prespecified questions that relate to attention and hyperactivity problems</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>The CBCL/1.5-5 questionnaire is a parent-completed questionnaire used for assessing behavioral problems and social competencies. It includes approximately 100 items that describe specific kinds of behavioral, emotional, and social problems that characterize preschool children between the ages of 1.5 and 5 years. Scores above the 97th percentile are in the significant range of clinical concern.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants indicated as needing further evaluation after completion of the Modified Checklist for Autism in Toddlers - Revised with Follow-Up (M-CHAT-R/F)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>The M-CHAT-R/F is a parent-reported autism screening tool designed to identify children 16 to 30 months of age who should receive a more thorough assessment for possible early signs of autism spectrum disorder (ASD) or developmental delay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants referred for neurological evaluation to determine diagnosis of cerebral palsy</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Cerebral palsy, defined as a chronic, nonprogressive neurologic disorder encompassing impaired motor function affecting movement, posture, balance muscle control, coordination, tone, or reflexes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants with at least 1 of the indicators of neurodevelopmental impairment</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>The indicators of neurodevelopmental impairment are: 1) Hearing impaired, uncorrected even with aids 2) Blindness in 1 or both eyes, or sees light only, 3) Cerebral palsy (moderate and severe), 4) Cognitive impairment: BSID-III Cognitive Scale Score of &lt;2 SDs below mean score (&lt;70), 5) Motor impairment: BSID-III Motor Composite Scale Score of &lt;2 SDs below mean score (&lt;70)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parental productivity loss related to a sick child and infant resource utilization in terms of number of hospital admissions</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Number of hospital admissions, proportion of infants with any hospital admission, post-birth hospitalization discharge, by principal and secondary discharge diagnosis, type of hospital unit admitted to (example neonatal intensive care unit [NICU], Pediatric, pediatric intensive care unit [PICU], Nursery level 3, intensive care unit [ICU]), and length of hospital stay per unit after 28 days post EDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parental productivity loss related to a sick child and infant resource utilization in terms of combined length of hospital stay for all hospital admissions</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Combined length of hospital stay in days for all hospital admissions (for infants discharged from the delivery hospitalization and for babies who were never discharged home post-delivery) after 28 days post EDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parental productivity loss related to a sick child and infant resource utilization in terms of number of emergency room/urgent care (ER/UC) visits and number of subjects with any ER/UC visit after 28 days post EDD</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Number of emergency room/urgent care (ER/UC) visits and number of subjects with any ER/UC visit after 28 days post EDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parental productivity loss related to a sick child and infant resource utilization in terms of number of surgical procedures</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>This outcome will be assessed by the type of procedure and whether performed on an inpatient basis or at an outpatient/surgical center) after 28 days post EDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parental productivity loss related to a sick child and infant resource utilization in terms of number of speciality care or therapy visits and number of subjects referred for speciality care or therapy</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>This outcome will be assessed by the type of speciality care or therapy after 28 days post EDD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of infants and children with at least 1 of the indicators of neurodevelopmental impairment at the end of the study</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The indicators of neurodevelopmental impairment are: 1) Hearing impaired, uncorrected even with aids 2) Blindness in 1 or both eyes, or sees light only 3) Cerebral palsy (moderate and severe 4) Diagnosis of ASD, ADD or ADHD</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Obstetric Labour, Premature</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All infants and children exposed to placebo during their mother's participation in a Phase III SPTL treatment study for SPTL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retosiban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All infants and children born to women who received at least 1 dose of retosiban in SPTL treatment study treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atosiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All infants and children born to women who received at least 1 dose of atosiban in SPTL treatment study treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will include the pooling of placebo and atosiban into a group called all comparators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retosiban</intervention_name>
    <description>This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.</description>
    <arm_group_label>Retosiban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.</description>
    <arm_group_label>Atosiban</arm_group_label>
    <arm_group_label>All comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>All comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mother is randomly assigned and dosed (retosiban or comparator) in 1 of the Phase III
             SPTL retosiban clinical studies.

          -  Infant is alive at 28 days post EDD.

          -  Written informed consent is obtained from the parent(s) or legal guardian(s) of the
             infant. The parent/legal guardian of participants aged 12 to 17 years must also
             provide written agreement for the infant to participate in the study where required by
             applicable regulatory and country or state requirements.

        Exclusion Criteria:

          -  There are no formal exclusion criteria for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Weeks</minimum_age>
    <maximum_age>20 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande Do Sul</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>273-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8760</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>989-3126</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tochigi</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>206-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seongnam</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-081</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Obregon</city>
        <state>Sonora</state>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunderland</city>
        <state>Tyne &amp; Wear</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oldham</city>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infants</keyword>
  <keyword>retosiban</keyword>
  <keyword>Preterm Labor</keyword>
  <keyword>long-term safety follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

